Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00709_DB01610_nanopub.RAevPbl-FHgZ8AZwxKWno7ePLqbos-qZCYJwZwLaMQZgo#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00709_DB01610 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00709_DB01610 label "DDI between Lamivudine and Valganciclovir - The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended. [drugbank_resource:DB00709_DB01610]" assertion.
- drugbank_resource:DB00709_DB01610 identifier "drugbank_resource:DB00709_DB01610" assertion.
- drugbank_resource:DB00709_DB01610 title "DDI between Lamivudine and Valganciclovir - The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended." assertion.
- drugbank:DB01610 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00709_DB01610 assertion.
- drugbank:DB00709 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00709_DB01610 assertion.